Acetazolamide Extended-Release NDC 42571-243

NDC codes

FDA NDC Directory

Product NDC (as listed)42571-243Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42571-0243Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
42571-243-01	42571024301	100 CAPSULE in 1 BOTTLE (42571-243-01)Marketed from Dec 1, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Acetazolamide Extended-Release
Generic name (nonproprietary): acetazolamide extended-release
Active ingredients: Acetazolamide — 500 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Micro Labs Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 207401
Marketing start: Dec 1, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Carbonic Anhydrase Inhibitors (Mechanism)Sulfonamides (Chemical structure)
Identifiers: Product ID 42571-243_456f5ce4-6ad1-f0a1-e063-6294a90a0facSPL ID 456f5ce4-6ad1-f0a1-e063-6294a90a0facSPL set ID 78f78919-a6ba-4072-bc45-2ab3637ed894RxCUI 562524UNII O3FX965V0IUPC 0342571243012
Pharmacologic class: Carbonic Anhydrase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442571024301 followed by a unit qualifier and the quantity

Package 42571-0243-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 8, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE: For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide extended-release capsules are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 207401

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 207401
Product	Strength	Form · route	Labeler	Product NDC
Acetazolamide Extended-Release	Acetazolamide 500 mg/1	CapsuleOral	AvPAK	50268-042